Brain tumor, breast cancer, colon cancer, congenital heart disease, heart arrhythmia. See more conditions.
Results filtered:Study status:
Closed for Enrollment
The purpose of this study is to monitor and better understand the health issues of people with bleeding disorders.
The purpose of this study is to compare recombinant Von Willebrand Factor (rVWF) vs. Tranexamic Acid (TA) to minimize menorrhagia in women with Type 1 Von Willebrand disease.
The purpose of this study is to determine the percentage of subjects with confirmed inhibitors (per CDC laboratory criteria; >0.5 Nijmegen Bethesda Units for hemophilia A and >0.3 Nijmegen Bethesda Units for hemophilia B within the first 50 Exposure Days (ED).
This trial is conducted in Europe and the United States of America. The aim of this trial is to compare the pharmacokinetics (the exposure of the trial drug in the body) of nonacog beta pegol (N9-GP) and ALPROLIX® in patients with haemophilia B.
The purpose of this study is to develop consensus guidelines and establish baseline outcomes data for various clinical complications and procedural events requiring treatment in the population of patients.
The purpose of this study is to determine if people with type 1 VWD experience age related increases in VWF levels and what effect this has on bleeding in this population. In order to discover this, the study will examine medical history, blood and genetic tests for VWD and bleeding and collect information about bleeds from the subjects.
Mayo Clinic is a nonprofit organization and proceeds from Web advertising help support our mission. Mayo Clinic does not endorse any of the third party products and services advertised.
A single copy of these materials may be reprinted for noncommercial personal use only. "Mayo," "Mayo Clinic," "MayoClinic.org," "Mayo Clinic Healthy Living," and the triple-shield Mayo Clinic logo are trademarks of Mayo Foundation for Medical Education and Research.